Signaling its continued commitment to addressing the anatomy of the
entire peripheral vasculature and combating disease with targeted
diagnostic and interventional devices, Cook
Medical is presenting its latest advancements at the ISET
2010 International Symposium on Endovascular Therapy. In addition to
live and simulated device demonstrations in booth #208, Cook’s
activities at the meeting include data presentations from two ongoing
clinical trials and breakout sessions on common and debilitating
conditions such as varicocele.
“The number of people affected by some form of peripheral vascular
disease is increasing at alarming rates worldwide”
“The number of people affected by some form of peripheral vascular
disease is increasing at alarming rates worldwide,” said Rob Lyles, vice
president and global leader of Cook’s peripheral intervention business
unit. “Awareness is a fundamental line of attack for us against these
spiking numbers. It is our mission to inform patients and physicians
alike about the intricacies surrounding treatments that span the entire
vascular disease spectrum and arm them with the technologies needed to
improve outcomes.”
Findings from the REFORM clinical trial evaluating the Formula™
Balloon Expandable Stent for the long-term treatment of renal artery
stenosis following suboptimal angioplasty are being presented by Dr.
Robert Bersin, medical director of endovascular services at Seattle
Cardiology and Swedish Medical Center. Early data from the single-arm,
100-patient study suggest high technical and procedural success rates,
clinically significant reductions in systolic blood pressure at one
month, stable renal function, and no evidence of safety concern.
Clinical follow-up will continue through three years, and enrollment for
the European arm of a trial evaluating a drug-eluting version of the
Formula stent for renal indications is scheduled to be announced at the LINC
meeting in Germany later this month.